The latest trends in peptide drug discovery and future challenges

Laszlo Otvos

DOI: https://doi.org/10.1080/17460441.2024.2365969

2024-06-13

Expert Opinion on Drug Discovery

Abstract:KEYWORDS: Designer peptide drugs have finally come of age. Ten years ago, we surveyed the state-of-the-art of peptide-based drug development and made recommendations to achieve blockbuster peptide therapeutics [ Citation 1 ]. By the time of our latest review last year [ Citation 2 ], not because of our recommendations, but rather in spite of them, multibillion dollar peptide drugs became a reality. Let's try again. When peptide drugs were waking up at the beginning of this millenium, everything was on the table driven by peptide chemistry and biology but not patient needs and pharmacology restrictions. Now, as major and minor peptide-based drugs have become a reality, a careful review of the success stories reveals undeniable trends and directions of the landscape. While original early peptide drug research is usually carried out by biotech and later stage by big pharma, the overriding characteristics appear to be the same. Below I support the prevailing concepts, as I see them, by using the examples of ADP355, our adiponectin receptor agonist peptide that has not reached approval, but is in various phases of clinical trials ().

pharmacology & pharmacy

What problem does this paper attempt to address?

The paper "Recent Trends and Future Challenges in Peptide Drug Discovery" mainly discusses the latest trends and challenges in peptide drug development. The author, Laszlo Otvos, points out that most successful peptide drugs are receptor agonists or natural hormone replacement therapies. As an example, the author presents their own research on ADP355, a leptin receptor agonist, to illustrate these trends.

1. **Key observations**: The paper mentions that current peptide drugs primarily focus on receptor agonists for replacement therapy, especially for the treatment of hormone deficiency or insufficiency. While the technology to convert receptor agonists into antagonists is mature, the majority of successful drugs are still agonists. Furthermore, designing fusion peptides can act on two receptors, expanding the range of disease targets.

2. **Specific considerations**: The paper emphasizes the importance of optimizing the amino acid composition to improve drug properties, patent protection, and chemical space expansion. The use of non-natural amino acids helps enhance circulation time and activity. Additionally, the challenges in in vitro and in vivo efficacy screening are discussed, such as reliable target binding and pharmacokinetic measurements.

3. **Expert opinions**: The rise of lifestyle drugs has increased the demand for peptide drugs, even if they are not necessarily administered orally. The author notes that although the manufacturing process of peptide drugs is still expensive and environmentally unfriendly, the prospects for peptide therapy remain optimistic with technological improvements and market demand. The multifunctionality of peptide drugs allows them to target multiple illnesses, contributing to investment returns.

In summary, the paper focuses on understanding the development trends of peptide drugs to overcome challenges and meet patient needs and market changes, while also considering environmental protection and cost-effectiveness.